MTSR - Metsera Inc.

70.5
-0.250   -0.355%

Share volume: 27,908,901
Last Updated: 11-13-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$70.75
-0.25
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
34.26%
3 Months
116.32%
6 Months
153.32%
1 Year
166.04%
2 Year
166.04%
Key data
Stock price
$70.50
P/E Ratio 
0.00
DAY RANGE
$70.13 - $70.78
EPS 
-$1.69
52 WEEK RANGE
$12.30 - $83.86
52 WEEK CHANGE
$166.04
MARKET CAP 
2.984 B
YIELD 
N/A
SHARES OUTSTANDING 
105.056 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-26-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$6,615,276
Company detail
CEO: Christopher Whitten Bernard
Region: US
Website: metsera.com
Employees: 81
IPO year: 2025
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Our principal executive offices are located at 3 World Trade Center, 175 Greenwich Street, New York, New York.

Recent news